Spectroscopic system employing a plurality of data types

• US 6,385,484 B2
• Filed: 12/15/2000
• Issued: 05/07/2002
• Est. Priority Date: 12/23/1998
• Status: Expired due to Term

• Current Assignee: Luma Imaging Corp. (SpectraScience, Inc.)
• Original Assignee: MediSpectra, Inc. (SpectraScience, Inc.)
• Inventors: Flewelling, Ross, Kaufman, Howard, Costa, Peter J., Nordstrom, Robert J., Hui, Kwong
• Primary Examiner(s): Lateef, Marvin M.
• Assistant Examiner(s): QADERI, RUNA S
• Application Number:
  US09/738,613
• Publication Number:
  US 20010020132A1
• Time in Patent Office: 508 Days
• Field of Search: 600/310, 600/473, 600/476, 600/478
• US Class Current: 600/476
• CPC Class Codes: A61B 5/0059 using light, e.g. diagnosis by transillumination, diascopy, fluorescence A61B5/0093, A61B5/1455, A61B5/02416 and A61B5/0261 take precedence
• CPC Class Codes: A61B 5/0068 Confocal scanning

Abstract

A system and method for classifying specimens using a plurality of spectral data types. Spectra are recorded as amplitudes at a series of discrete wavelengths. Pluralities of reference spectra are recorded for specimens having known conditions. A spectrum of a first type is observed for a test specimen. The specimen is characterized as to a first known condition. In the event that the specimen does not exhibit the first known condition, a spectrum of a second type is observed and analyzed to determine which of a plurality of conditions is to be ascribed to the test specimen. In some embodiments, the test specimen can comprise human cervical tissue, and the known conditions can include normal health, metaplasia, CIN I and CIN II/II.

Claims

1. A method of determining a condition of a test specimen, said method comprising,

identifying a plurality of first test specimens having a first known condition and observing from each of said first test specimens a first fluorescence spectrum characteristic of said first known condition,

obtaining an average reflectance spectrum from said plurality of first test specimens,

obtaining a reflectance spectrum from a second test specimen that is observed to produce a second fluorescence spectrum that is not characteristic of said first known condition,

obtaining a reflectance spectrum residual by subtracting said average reflectance spectrum from said reflectance spectrum obtained from said second test specimen, and

determining said condition of said second test specimen based at least in part on an amplitude of one or more features of said reflectance spectrum residual.

2. The method of claim 1, wherein said plurality of first test specimens comprise a plurality of first tissue specimens and said second test specimen comprises a second tissue specimen.

3. The method of claim 2, wherein said plurality of first tissue specimens and said second tissue specimen comprise human cervical tissue, said first known condition is a known state of health, and said condition of said second test specimen is a state of health to be determined.

4. The method of claim 2, wherein said known state of health comprises one of the conditions of normal squamous tissue, metaplasia, CIN I, and CIN II/III.

5. The method of claim 1, further comprising,

obtaining additional optical information from said second test specimen, and

evaluating said additional optical information with said fluorescence spectrum and said reflectance spectrum from said second test specimen to determine said condition of said second test specimen.

6. The method of claim 5, wherein said additional optical information comprises video information.

7. The method of claim 5, wherein said additional optical information comprises an optical image.

8. The method of claim 5, wherein said plurality of first test specimens comprise a plurality of first tissue specimens and said second test specimen comprises a second tissue specimen.

9. The method of claim 8, wherein said plurality of first tissue specimens and said second tissue specimen comprise human cervical tissue, said first known condition is a known state of health, and said condition of said second test specimen is a state of health to be determined.

10. The method of claim 8, wherein said known state of health comprises one of the conditions of normal squamous tissue, metaplasia, CIN I, and CIN II/III.

11. A spectroscopic system for determining a condition of a test specimen, comprising,

a data collection module that observes a first fluorescence spectrum characteristic of a first known condition from each of a plurality of first test specimens having said first known condition, that observes a first reflectance spectrum from each of said plurality of first test specimens, and that observes a reflectance spectrum from a second test specimen that is observed to produce a second fluorescence spectrum that is not characteristic of said first known condition,

a computation module that compute an average reflectance spectrum from said first reflectance spectrum from each of said plurality of first test specimens, and that computes a reflectance spectrum residual by subtracting said average reflectance spectrum from said reflectance spectrum obtained from said plurality of second test specimens, and

an analysis module that determines a condition of said second test specimen based at least in part on an amplitude of one or more features of said reflectance spectrum residual.

12. The system of claim 11, wherein said plurality of first test specimens comprise a plurality of first tissue specimens and said second test specimen comprises a second tissue specimen.

13. The system of claim 12, wherein said plurality of first tissue specimens and said second tissue specimen comprise human cervical tissue, said first known condition is a known state of health, and said condition of said second test specimen is a state of health to be determined.

14. The system of claim 12, wherein said known state of health comprises one of the conditions of normal squamous tissue, metaplasia, CIN I, and CIN II/III.

15. The system of claim 11, wherein said data collection module obtains additional optical information from said second test specimen, and

said analysis module evaluates said additional optical information with said fluorescence spectrum and said reflectance spectrum from said second test specimen to determine said condition of said second test specimen.

16. The system of claim 15, wherein said additional optical information comprises video information.

17. The system of claim 15, wherein said additional optical information comprises an optical image.

18. The system of claim 15, wherein said plurality of first test specimens comprise a plurality of first tissue specimens and said second test specimen comprises a second tissue specimen.

19. The system of claim 18, wherein said plurality of first tissue specimens and said second tissue specimen comprise human cervical tissue, said first known condition is a known state of health, and said condition of said second test specimen is a state of health to be determined.

20. The system of claim 18, wherein said known state of health comprises one of the conditions of normal squamous tissue, metaplasia, CIN I, and CIN II/III.

21. A method of determining a disease state in a specimen, the method comprising the steps of:

obtaining a reflectance spectrum from a test specimen having a fluorescence spectrum that is not characteristic of a healthy tissue;

subtracting an average reflectance spectrum obtained from a plurality of specimens from said reflectance spectrum to produce a reflectance spectrum residual, each producing a fluorescence spectrum characteristic of healthy tissue; and

determining disease state in said test specimen based upon one or more characteristics of said reflectance spectrum residual.

22. The method of claim 21, wherein said test specimen is selected from the group consisting of cervical tissue, intestinal tissue, esophageal tissue, and skin tissue.

23. The method of claim 21, wherein said disease state is selected from the group consisting of normal squamous tissue, metaplasia, CIN I, and CIN II/III.